Generic Name: ixekizumab
Brand Name: Taltz
Manufacturer: Eli Lilly Canada Inc.
Therapeutic Area: Arthritis, psoriatic
Indications: Arthritis, psoriatic
Manufacturer Requested Reimbursement Criteria1: To be reimbursed for the treatment of adult patients with active psoriatic arthritis (PsA), used alone or in combination with methotrexate, when the response to previous conventional disease-modifying antirheumatic drugs (cDMARDs) therapy has been inadequate.
Submission Type: New Indication
Project Status: Complete
Biosimilar: No
Date Recommendation Issued: August 21, 2018
Recommendation Type: Reimburse with clinical criteria and/or conditions
Fee Schedule: Schedule B
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Key Milestones2 | |
|---|---|
| Call for patient input posted | January 17, 2018 |
| Patient group input closed | March 08, 2018 |
| Clarification: - Patient input submission received | |
| Patient input summary sent for review to patient input groups | March 16, 2018 |
| Patient group comments on input summary closed | March 23, 2018 |
| Clarification: - Patient input summary feedback received | |
| Submission received | February 20, 2018 |
| Submission accepted for review | March 06, 2018 |
| Review initiated | March 07, 2018 |
| Draft CDR review report(s) sent to applicant | May 24, 2018 |
| Comments from applicant on draft CDR review report(s) received | June 04, 2018 |
| Redaction requests from applicant on draft CDR review report(s) received | June 11, 2018 |
| CDR review team's comments on draft CDR review report(s) sent to applicant | July 06, 2018 |
| Canadian Drug Expert Committee (CDEC) meeting | July 18, 2018 |
| CDEC recommendation & redacted CDR review report(s) sent to applicant and drug plans | July 30, 2018 |
| Embargo period ended and validation of redacted CDR review report(s) received | August 14, 2018 |
| CDEC Final Recommendation issued to applicant and drug plans | August 21, 2018 |
| CDEC Final Recommendation posted | August 23, 2018 |
| Final CDR review report(s) and patient input posted | August 31, 2018 |